All Type of News
Patent trial process Shortened to 4 months
The Korean Intellectual Property Office (KIPO) said on October 29 that Korea will have a position of the world's fastest patent trial processor.
Under the shortened process, patent disputes such as nullification tr...
Restructuring likely to sweep pharmaceutical industry
The accelerating downturn in consumer confidence due to a deadly cocktail of recession fears and subsequent plunge of asset values is making it harder for pharmaceutical companies to do business.
Analysts expect re...
Hanmi to introduce losartan genericHanmi Pharm plan to market Ozaltan tablets (losartan potassium) from November 3.
The company said the manufacture of Ozatan 50 mg and 100 mg is made available through its own...
|
AstraZeneca Korea to launch fulvestrant, new treatment option for advanced breast cancerAstraZeneca Korea has announced that it will launch fulvestrant (Faslodex 250mg), a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women ...
|
Bukwang announces effectiveness of Adipocell in IFATS 2008
Bukwang said that Adipocell (allogenic adipose-derived stem cell) injection, which was developed by Anterogen, its affiliate company, is clinically effective in areas such as tissue repair and wound healing in Phase I...
Korea to host 2008 Xpo Pharm and Xpo ChemKorea is once again making a bid to become one of the global pharmaceutical and chemical traders, with 2008 Xpo Pharm and Xpo Chem kicking off between November 5 and 6.
Co-or...
|
.jpg)
Ilyang gets nod for ilaprazole in KoreaIlyang Pharmaceutical Co., Ltd., announced on October 28 that they received marketing approval from the Korean Food and Drug Administration (KFDA) for ilaprazole a new investiga...
|
Daewoong to conduct phase I trial for investigational neuropathic pain product
Daewoong Pharm says it will conduct a phase I study for its investigational neuropathic pain product (DWP05195) after approval from the Korea Food and Drug Administration.
According to the company, the phase I stud...
VM202 selected as Biostar research project
The ministry of Knowledge Economy has announced that ViroMed Co.’s VM202 (DNA-based medicine for ischemic disease including peripheral and coronary artery disease) has been designated as one of the nation’s Biostar re...
New antibody developed to fight pancreatic cancer
The Ministry of Education, Science and Technology announced on October 28 that Korean scientists have developed a novel antibody that may repress PAUF protein linked to metastasis of pancreatic cancer, opening new pos...
